Clinical trials: Apolipoprotein L1
Chronic Kidney Diseases, Apolipoprotein L1
APOL1 Genetic Testing Program for Living Donors
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves.
- Conditions
- Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
- Trial name
- NCT04910867
- Testing
- Components of Genetic Counseling, APOL1 genetic testing, EHR integration
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- Northwestern University
Transplant;Failure,Kidney, Kidney Disease
APOL1 Gene Variants in African American Kidney Transplant Recipients
Aim 1: Determine if there is an association between the APOL1 risk variants and allograft survival and function in African Americans Aim 2: Determine if there is an association between the presence of APOL1 risk variants in an…
- Conditions
- Transplant;Failure,Kidney, Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT01442402
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Brigham and Women's Hospital
Kidney Diseases, Transplant Failure
Evaluation of APOL1 Gene Variants in Kidney Donors and Their Impact on Long-term Renal Function in Donors and Recipients
Evaluation of the frequency of APOL1 gene variants in kidney donors and the impact of these variants on the long-term renal function of kidney transplant donors and recipients.
- Trial name
- NCT06116721
- Where
- Brazil
- Volunteers
- 2,450 people
- Sponsor
- Hospital do Rim e Hipertensão
Chronic Kidney Diseases
Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1)
Chronic kidney disease (CKD) is a major global public health issue. The present project focuses on the role of apolipoprotein L1 (APOL1) in patients with stage 4 CKD (glomerular filtration rate between 15 and 29 mL/min/1.73 m²).
- Trial name
- APOL1 (NCT07288723)
- Where
- Guadeloupe
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Chronic Kidney Diseases, Genetic Predisposition
APOL1 Genetic Testing Program for Living Donors, Part 2
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves.
- Trial name
- NCT04999436
- Testing
- APOL1 Counseling Training Program
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Kidney Disease
ACTH Treatment of APOL1- Associated Nephropathy
The purpose of this research study is to determine if the study drug H.C. Acthar gel slows the progression of your kidney disease.
- Trial name
- NCT02006849
- Testing
- Acthar
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
This is a multicentric retrospective observational cohort study. As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, APOL1 Associated Kidney Disease
- Trial name
- NEPHROL1 (NCT06443034)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris